Analysis of malignancy of oral cancer and application of therapy for oral cancer by gene technology

对131例口腔鳞状细胞癌p130的免疫组化研究表明，p130在许多高分化癌和低度恶性肿瘤中呈阳性表达，在口腔恶性黑色素瘤中，p130在生存期超过10年的病例中呈阳性表达，p53在生存期低于1年的病例中呈阳性表达低度不典型增生者p130、Rb蛋白表达阳性，高度不典型增生者p53蛋白表达阳性。提示p130、Rb和p53的免疫组化检测有助于预测口腔白斑的临床病程，口腔鳞癌组织和口腔鳞癌细胞系中均未发现β-catenin基因突变。而β-catenin蛋白在细胞核和胞浆中聚集，EGFR的表达与β-catenin蛋白的酪氨酸磷酸化有关，认为检测β-catenin基因对分析口腔癌恶性程度是有效的。

Immunohistochemical investigation of 131 oral squamous cell carcinomas with p130 revealed that positive staining with p130 was found in many well-differentiated carcinomas and low-grade malignancy cases.In oral malignant melanoma, p130 positively was recognized in the cases of which survival period was over 10 years and p53 positively was recognized in the cases of which survival period was below 1 year.In oral leukoplakie which is precancerous lesion, positive staining with p130 and Rb was shown in the cases with low grade of dysplasia and positive staining with p53 was shown in the cases with high grade of dysplasia. It is suggested that immunohistochemical examination with p130, Rb and p53 is helpful for predicting the clinical course of oral leukoplakie.β-catenin gene mutation was not recognized in oral squamous cell carcinoma cases and oral squamous cell carcinoma cell line. However, β-catenin protein was accumulated in the nuclei and the cytoplasm with the expression of EGFR which is related to tyrosin-phospholyration of β-catenin protein and it is thought that the examination of β-catenin gene is effective for analysis of degree of malignancy of oral cancer.